Ozempic

In a blockbuster franchise race, Novo’s Trulicity rival scores more promising late-stage diabetes data
In a blockbuster franchise race, Novo’s Trulicity rival scores more promising late-stage diabetes data
Endpoints
Novo Nordisk
Trulicity
Ozempic
Eli Lilly
diabetes
Flag link:
Anthem, HealthCore and Novo Nordisk for Partnership to Study Benefits New Type 2 Diabetes Drug Vs Other Available Drugs
Anthem, HealthCore and Novo Nordisk for Partnership to Study Benefits New Type 2 Diabetes Drug Vs Other Available Drugs
CP Wire
Anthem
Novo Nordisk
Ozempic
type 2 diabetes
Flag link:
Anthem, HealthCore and Novo Nordisk for Partnership to Study Benefits New Type 2 Diabetes Drug Vs Other Available Drugs
Anthem
Novo Nordisk
Ozempic
type 2 diabetes
Flag link:
Eli Lilly ushers up-and-coming GIP/GLP-1 drug into PhIII as Novo Nordisk rival wows with impressive results
Eli Lilly ushers up-and-coming GIP/GLP-1 drug into PhIII as Novo Nordisk rival wows with impressive results
Endpoints
Eli Lilly
diabetes
Novo Nordisk
Ozempic
LY3298176
Trulicity
Flag link:
Repurposing a GLP-1 diabetes drug to slow Parkinson’s disease
Repurposing a GLP-1 diabetes drug to slow Parkinson’s disease
Fierce Biotech
diabetes
Parkinson's Disease
GLP-1 agonist
AstraZeneca
Byetta
Bydureon
Novo Nordisk
Victoza
Ozempic
Eli Lilly
Trulicity
Peptron
Flag link:
5 Biggest Blockbuster Diabetes Drugs of the Future
5 Biggest Blockbuster Diabetes Drugs of the Future
Motley Fool
Eli Lilly
Trulicity
Novo Nordisk
Ozempic
Boehringer Ingelheim
Jardiance
Tresiba
NovoRapid
Flag link:
Novo reveals more Ozempic data on change in body weight by baseline BMI
Novo reveals more Ozempic data on change in body weight by baseline BMI
Yahoo/Reuters
Novo Nordisk
diabetes
BMI
Ozempic
Eli Lilly
Trulicity
Flag link:
Novo Nordisk results show GLP-1s are job 1. Can its crucial Ozempic launch deliver?
Novo Nordisk results show GLP-1s are job 1. Can its crucial Ozempic launch deliver?
Fierce Pharma
Novo Nordisk
GLP-1 agonist
diabetes
Ozempic
drug launches
Flag link:
Japan approves Novo Nordisk’s once-weekly Type II diabetes drug
Japan approves Novo Nordisk’s once-weekly Type II diabetes drug
Drug Delivery Business News
Japan
Novo Nordisk
diabetes
type 2 diabetes
Ozempic
Flag link:
12 blockbusters: The surging list of $1B-plus drugs rolling out on the market this year might surprise you
12 blockbusters: The surging list of $1B-plus drugs rolling out on the market this year might surprise you
Endpoints
drug launches
Hemlibra
Roche
Biktarvy
Gilead Sciences
Ozempic
Novo Nordisk
Erleada
JNJ
Shingrix
GSK
Patisiran
Alnylam
Sanofi
Epidiolex
GW Pharma
Aimovig
Amgen
Novartis
lanadelumab
Shire
Elagolix
AbbVie
Steglatro
Pfizer
Merck
Sublocade
Indivior
Flag link:
Novo Nordisk secures Ozempic formulary coverage from Express Scripts
Novo Nordisk secures Ozempic formulary coverage from Express Scripts
Fierce Pharma
Novo Nordisk
Ozempic
Express Scripts
Flag link:
Bring on Novo Nordisk’s semaglutide, Eli Lilly says. We’re ready
Bring on Novo Nordisk’s semaglutide, Eli Lilly says. We’re ready
Fierce Pharma
Novo Nordisk
semaglutide
Eli Lilly
Ozempic
Trulicity
Flag link:
Novo Nordisk’s once-weekly Type II diabetes med approved in Europe
Novo Nordisk’s once-weekly Type II diabetes med approved in Europe
Drug Delivery Business News
Novo Nordisk
diabetes
type 2 diabetes
Europe
Ozempic
Flag link:
Novo Nordisk launches two new diabetes drugs in U.S.
Novo Nordisk launches two new diabetes drugs in U.S.
Drug Delivery Business News
Novo Nordisk
diabetes
Ozempic
Fiasp
Flag link:
Novo Nordisk’s once-weekly diabetes injection cleared in Canada
Novo Nordisk’s once-weekly diabetes injection cleared in Canada
Drug Delivery Business News
Novo Nordisk
diabetes
Canada
Ozempic
Flag link:
5 Biggest New Drugs of 2018
5 Biggest New Drugs of 2018
Motley Fool
Gilead Sciences
Bictegravir/F/TAF
Novo Nordisk
semaglutide
Ozempic
Incyte
epacadostat
AbbVie
Rova-T
Celgene
ozanimod
Flag link:
Novo gains FDA OK for semaglutide
Novo gains FDA OK for semaglutide
BioPharma Dive
Novo Nordisk
semaglutide
FDA
Ozempic
type 2 diabetes
Flag link: